# Dixon Investments Inc – FDA 483, Mar 11, 2025

Source: https://www.keypedia.com/records/483/dixon-investments-inc/58bab81c-91b1-4be5-ab36-d85a318f0160

> FDA 483 for Dixon Investments Inc on March 11, 2025. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Dixon Investments Inc
- Inspection Date: 2025-03-11
- Product Type: drugs
- Office Name: Atlanta District Office
- Summary: Dixon Investments Inc, a drug manufacturer in Orchard Hill, GA, was inspected by the FDA and received a Form 483 with seven observations. The inspection revealed significant deficiencies in quality control unit procedures, batch record completeness, stability testing, cleaning and process validation, annual product reviews, computer system controls, and cGMP employee training. Several issues, including process validation, were noted as repeat observations, indicating persistent non-compliance.

## Related Documents

- [WARNING_LETTER - 2025-03-11](https://www.keypedia.com/records/warning_letter/dixon-investments-inc/e32a11d5-1d68-4faf-815e-e68cab540db2) — date: March 11, 2025
- [483 - 2019-03-22](https://www.keypedia.com/records/483/dixon-investments-inc/a5d5d5be-99cc-4091-8d68-9db489700ed0) — date: March 22, 2019

## Related Officers

- [Samantha E. Cleek](https://www.keypedia.com/people/samantha-e-cleek/7305f28f-9c92-427d-86ec-42c0bb6bf3ce)

Company: https://www.keypedia.com/companies/dixon-investments-inc/ce191609-e6f1-4391-8f04-21996703095d

Office: https://www.keypedia.com/offices/atlanta-district-office/7586d99a-288e-49d1-8c3d-d88b7354b7a7